Helicobacter pylori Infection Testing — CPB 0177 | AETNA Coverage Update

Aetna modified CPB 0177 for H. pylori infection testing, effective September 26, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated its H. pylori testing coverage policy under CPB 0177 in Aetna's clinical policy bulletin system. The revision expands the list of covered indications for urea breath testing (CPT 78267, 78268, 83013, 83014) and stool antigen testing (CPT 87338), and adds explicit medical necessity criteria for nucleic acid amplification resistance testing (CPT 87513). If your practice bills for gastroenterology, bariatric surgery, or primary care in 2025, this change touches your workflow.

Quick-Reference Table

Aetna H. Pylori Testing Coverage Criteria and Medical Necessity Requirements 2025

The Aetna H. pylori testing coverage policy under CPB 0177 is built around one core idea: testing is covered when there's a documented clinical reason to act on the result. Aetna does not cover H. pylori testing as routine screening. Your claim needs a supported indication from the list below, or it will deny.

For active infection testing, Aetna considers FDA-cleared carbon isotope urea breath testing (¹³C or ¹⁴C) and stool antigen testing (HpSA) medically necessary. The covered CPT codes for urea breath testing are 78267 (C-14 acquisition), 78268 (C-14 analysis), 83013 (C-13 breath test analysis), and 83014 (drug administration). Stool antigen testing bills under CPT 87338.

There are 15 covered indications. The list expanded with this policy revision. New or clarified additions include persons with gastric premalignant conditions (GPMC) and persons with hyperplastic or adenomatous gastric epithelial polyps (GEP). These additions align CPB 0177 with updated guidelines from the American Gastroenterological Association and the American College of Gastroenterology.

One medical necessity rule deserves close attention on eradication testing: Aetna requires the test occur no sooner than four weeks post-treatment. Bill CPT 83013 or 87338 for eradication confirmation before the four-week mark, and you're looking at a claim denial. Document the treatment end date in the chart before billing.

The GPMC indication comes with an important note. Aetna expects that H. pylori eradication is confirmed before the endoscopic surveillance examination. Active H. pylori infection can distort the endoscopic and histologic appearance of GPMC. That means the sequencing of testing and surveillance matters for both clinical and billing purposes.

Aetna also considers nucleic acid amplification for clarithromycin resistance testing medically necessary. This applies to treatment-experienced patients with persistent H. pylori infection — not first-line workups. Bill CPT 87513 for this indication. The policy also references CPT 0008U (Helicobacter pylori detection and antibiotic resistance, DNA) in the not-covered group, which is a meaningful distinction your billing team should flag.

This policy does not mention prior authorization as a blanket requirement for H. pylori testing. That said, prior auth requirements can vary by Aetna plan type. Check plan-level benefits before assuming coverage is automatic, especially for the newer indications like GPMC and GEP.

Aetna H. Pylori Testing Exclusions and Non-Covered Indications

CPT codes 83009, 83519, 86318, 86677, and 87632 are grouped under the not-covered category in CPB 0177. The same applies to CPT 0008U.

CPT 83009 (blood test analysis for urease activity) is specifically not covered. Aetna covers breath and stool-based testing — not blood-based urease testing. If your lab has been billing 83009 for H. pylori workups, stop. That claim will not be reimbursed under this policy.

CPT 86677 (H. pylori antibody) and CPT 86318 (single-step immunoassay for infectious agent antibody) are also not covered. Serology-based testing cannot confirm active infection — it only shows prior exposure. Aetna's position is consistent with clinical guidelines here. Blood antibody tests don't help you know if the infection is active, so Aetna doesn't pay for them in this context.

CPT 87632 (respiratory virus detection by nucleic acid) appearing in the not-covered group is likely a crossover artifact in the policy coding. Don't bill it for H. pylori indications.

Coverage Indications at a Glance

Aetna H. Pylori Billing Guidelines and Action Items 2025

This policy took effect September 26, 2025. If you haven't audited your charge capture since then, do it now.

1. Audit your active CPT codes for H. pylori billing.
Remove CPT 83009 and 86677 from any H. pylori order sets or charge capture tools if they're still present. Aetna will not reimburse these. The covered breath test codes are 78267, 78268, 83013, and 83014. Stool antigen testing is 87338. These are your billable options.

2. Add the GPMC and GEP indications to your documentation templates.
Gastric premalignant conditions and gastric epithelial polyps are now explicitly covered. Your gastroenterology and endoscopy teams may already be testing for H. pylori in these patients. Make sure the clinical documentation supports the indication — and that the ICD-10 maps correctly to C16.x, D13.1, or the relevant K-codes.

3. Enforce the four-week rule for eradication testing.
Build a hard stop — or at least a soft alert — in your EHR or order entry system. If a provider orders post-treatment H. pylori testing, the system should flag orders placed fewer than 28 days after treatment ended. A claim denial for premature eradication testing is an easy fix on the front end and a painful fix after the fact.

4. Sequence GPMC surveillance correctly.
For patients with gastric premalignant conditions, H. pylori eradication must be confirmed before the endoscopic surveillance exam. If your billing team sees a GPMC endoscopy claim and a same-date H. pylori test, that's a sequencing red flag. Document the testing date and the surveillance date separately, and make sure eradication was confirmed before the scope.

5. Reserve CPT 87513 for treatment-experienced patients only.
Clarithromycin resistance testing via nucleic acid amplification (CPT 87513) is medically necessary only for salvage regimen selection in patients who have failed prior H. pylori treatment. Don't bill it for initial workups. The chart needs to show prior treatment failure before this code will pass medical necessity review.

6. Check plan-level prior authorization requirements.
CPB 0177 doesn't impose blanket prior auth requirements, but Aetna plan types vary. Commercial HMO and managed Medicaid plans may apply prior authorization requirements on top of the base policy. Verify benefits before ordering testing for patients on less common Aetna plan types. If you're unsure how this applies to your payer mix, loop in your billing consultant before September 26, 2025 claims start aging.

CPT, HCPCS, and ICD-10 Codes for H. Pylori Testing Under CPB 0177

Covered CPT Codes (When Selection Criteria Are Met)

Not Covered / Experimental Codes

Key ICD-10-CM Diagnosis Codes

The full ICD-10 list under CPB 0177 includes 195 codes. The table above reflects the clinically primary groupings. Access the complete code set at app.payerpolicy.org/p/aetna/0177.